Glucose‐dependent insulinotropic polypeptide reduces postprandial glucose excursions but does not protect from hypoglycaemia in persons with type 1 diabetes—A randomised placebo‐controlled study
Primary result · Spread ± 0.5 (SE of the mean)Result — go to the resultDifference in postprandial maximum plasma glucose 1.5 mmol/LAuthors' conclusion
GIP did not prevent hypoglycaemia following excess prandial insulin and physical activity after meal ingestion in males with type 1 diabetes, but it reduced peak postprandial plasma glucose compared to GIP(3-30)NH2.
Study context
- Population
- Men with T1D given a standardised mixed meal with excess prandial insulin (125% of normal dose) followed by 30 min of intermediate resistance bicyclingcrossover, 3 study days
- Participants
- 12 men
- Comparison
- IV GIP vs GIP receptor antagonist GIPNH2 vs placebo
Methodological detailsplacebo-controlled, double-blind, crossover
- Placebo-controlled
- Double-blind
- Crossover
Primary result
Spread ± 0.5 (SE of the mean)
Difference in postprandial maximum plasma glucose
1.5 mmol/L
P = 0.048
As reported in the abstract
Further findings
Amount of glucose infused to avoid plasma glucose <2.5 mmol/L
- Similar on all three study days
C-peptide, insulin and glucagon levels
- No differences were found
Original publication
Glucose‐dependent insulinotropic polypeptide reduces postprandial glucose excursions but does not protect from hypoglycaemia in persons with type 1 diabetes—A randomised placebo‐controlled study. Diabetes Obes Metab. Published 28 December 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →